|1.||Kao, Jia-Horng: 28 articles (10/2015 - 01/2003)|
|2.||Kumada, Hiromitsu: 23 articles (03/2015 - 01/2003)|
|3.||Chen, Pei-Jer: 22 articles (06/2015 - 01/2003)|
|4.||Liu, Chun-Jen: 21 articles (09/2015 - 01/2003)|
|5.||Chen, Ding-Shinn: 20 articles (05/2015 - 01/2003)|
|6.||Ikeda, Kenji: 20 articles (03/2015 - 01/2003)|
|7.||Suzuki, Yoshiyuki: 18 articles (06/2014 - 01/2003)|
|8.||Suzuki, Fumitaka: 18 articles (07/2013 - 01/2003)|
|9.||Yokosuka, Osamu: 17 articles (05/2015 - 09/2003)|
|10.||Arase, Yasuji: 17 articles (03/2015 - 01/2003)|
04/01/2007 - "The results showed that the frequency and IFN-alpha-producing capacity of peripheral blood pDCs were dramatically reduced and relatively inversely correlated with the level of serum alanine aminotransferase in both groups of patients with chronic genotype B and C HBV infection. "
10/28/2013 - "During pregnancy in women with chronic HCV infection a significant reduction in mean alanine aminotransferase levels has been reported, with a rebound during the postpartum period. "
03/01/2005 - "The efficacy of serum alanine aminotransferase (ALT) levels in predicting the severity of hepatitis C virus (HCV) infection is unclear. "
08/19/2003 - "However, whereas GBV-B was eliminated from one animal by 20 weeks, the second animal remained viremic (103 to 107 genome equivalents per ml) for >2 years, with alanine transaminase levels becoming elevated again before spontaneous resolution of the infection. "
02/01/2015 - "The study addresses the utility of real-time quantitative polymerase chain reaction (RQ-PCR) in the diagnosis and monitoring of HCV infection especially on seronegative and normal serum alanine aminotransferase (ALT) HD patients. "
|2.||Body Weight (Weight, Body)
09/01/2003 - "Whereas, when rats were fed on LCD protocol, their body weight (329.5+/-38.4 g, P<0.01), abdominal adipose content (310.21+/-1.52 g, P<0.05), liver index (3.199+/-0.552 %, P<0.05), and serum alanine aminotransferase (683.03+/-245.49 nkat/L, P<0.05) were significantly decreased, and the degree of hepatic steatosis (P<0.05) was markedly improved compared with those in the NASH group. "
06/01/2008 - "Alanine aminotransferase significantly improved from baseline with decreasing body weight in both groups (MET: 35 [range, 21-43] to 32 [20-46] U/L; control: 66 [28-121] to 33 [14-45] U/L; P<or=0.01). "
11/01/1990 - "For every 1% reduction in body weight, alanine aminotransferase activity improved by 8.1%. "
01/01/2012 - "Body weight (BW), body mass index (BMI), FBG and PPBG were measured every 4 weeks and serum transaminase (SGPT) was measured at the beginning and at the end of the study. "
07/01/2014 - "To detect differences in the basic phenotype of this animal model, lifespan, body weight (BW), and serum alanine aminotransferase (ALT) level were evaluated. "
05/01/2015 - "In addition, based on studies with certain clinical measurements data, G allele carriers were more likely to have higher level of serum alanine aminotransferase (ALT) (standard mean difference [SMD] = 7.03, 95% CI: 2.47-11.60), and higher fibrosis score (SMD = 0.39, 95% CI: 0.18-0.60). "
08/01/2011 - "Advanced fibrosis was defined as liver stiffness > 9 kPa for patients with normal alanine aminotransferase (ALT) or > 12 kPa for those with elevated ALT according to previous validation study. "
05/01/2010 - "However, in active CHB with elevated alanine aminotransferase (ALT) levels, the positive predictive value for diagnosing cirrhosis is poor, and further studies are needed to optimize the use of transient elastography in this important group."
02/01/2009 - "Insignificant and advanced fibrosis was defined as an LSM of 6.0 kPa or less, and greater than 9.0 kPa for patients with alanine aminotransferase (ALT) levels less than or equal to the f upper limit of normal (ULN), and 7.5 kPa or less and greater than 9.0 kPa for those with ALT levels between 1 and 5 x ULN, respectively, based on a previous study with histologic validation. "
05/01/2007 - "The study group consisted of 50 patients with HCV-related cirrhosis with transaminase values less than twofold increased (alanine aminotransferase [ALT] < 80 IU/L). "
|4.||Liver Diseases (Liver Disease)
11/01/2014 - "Serum alanine aminotransferase (ALT) is important for screening, diagnosis and management of chronic liver diseases. "
01/01/2015 - "Alanine aminotransferase levels and scores on the Chronic Liver Disease Questionnaire improved to a significantly greater extent in the highest dose group (P=0.007 and P=0.021, respectively). "
08/01/1994 - "On the other hand, there was no significant rise in the level of sCD4 in patients with any liver disease, except FH, no definite relationship between sCD4 and sGPT, and no consistant tendency in sCD4 levels between exacerbation and remission. "
04/01/2010 - "SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease."
11/01/2009 - "This study presents the initial demonstration of characterizing metabolic state differences in the liver with hyperpolarized (13)C spectroscopy and shows the ability to detect physiological perturbations in alanine aminotransferase activity, which is an encouraging result for future liver disease investigations with hyperpolarized magnetic resonance technology."
01/01/2016 - "In acute hepatitis patients who eventually cleared HBV, IDO activity, chemokine (C-X-C motif) ligand 9 (CXCL9), CXCL10, and CXCL11 increased at the peak of alanine aminotransferase. "
12/01/2000 - "GB virus-B (GBV-B) causes an acute hepatitis in tamarins characterized by increased alanine transaminase levels that quickly return to normal as the virus is cleared. "
04/01/2015 - "Multiple studies have recently proposed the lowering of upper limit of normal (ULN) for alanine aminotransferase (ALT) to improve the diagnostic sensitivity for viral hepatitides and metabolic syndrome (MS). "
11/01/2008 - "This study elucidates the changing aetiology of alanine transaminase elevation (ALT levels >40 IU/L) in a previously hepatitis-endemic township. "
09/01/1998 - "In the two treatment trials, pooled analysis of the patients with mild hepatitis showed that 36.4% of them normalized serum alanine aminotransferase and remained virus negative (sustained response) after completing an 18-24 month course of IFN vs 15.3% for a 6-month course and no response in the absence of treatment. "
|1.||Aspartate Aminotransferases (Aspartate Transaminase)
|4.||DNA (Deoxyribonucleic Acid)
|7.||Hepatitis B e Antigens
|10.||RNA (Ribonucleic Acid)
|5.||Transplantation (Transplant Recipients)